Tel Aviv, Israel - April 12, 2024 - PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive Officer of PainReform participated in an interview with "The Big Biz Show," an Emmy Award-winning nationally syndicated TV and radio show.

During the interview, Mr. Hadar discussed the benefits for patients using PRF-110, the Company's proprietary extended-release drug-delivery system, which provideslonger-lasting relief without the need for repeated dose administration but also significantly impacts the global effort to reduce opiate use.

The interview aired on cable TV and streaming services, including Roku, as well as on radio via The Biz Talk Radio Network, Armed Forces Radio, and iHeart Media in 175 countries.

To access the full interview please click here.

Podcasts of the show are available on iHeart Radio, Apple Podcasts, Speaker.com, and TuneIn, as well as to subscribers of biztv.com or ytaclub.com.

About the Big Biz Show

Widely regarded as "Business with a Bite," the Big Biz Show is an Emmy Award-winning nationally syndicated radio and TV program. The fast-talking, hard-hitting show is hosted by Bob "Sully" Sullivan, who is also a weekly contributor on the FOX Business Network. For more information, go to bigbizshow.com.

About PainReform

PainReform is a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics. PRF-110, the Company's lead product is based on the local anesthetic ropivacaine, targeting the postoperative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed prior to closure to provide localized and extended postoperative analgesia. The Company's proprietary extended-release drug-delivery system is designed to provide an extended period of post-surgical pain relief without the need for repeated dose administration while reducing the potential need for the use of opiates. For more information, please visit www.painreform.com.

Contact:
Crescendo Communications, LLC
Tel: 212-671-1021
Email: prfx@crescendo-ir.com

Ilan Hadar
Chief Executive Officer
PainReform Ltd.
Tel: +972-54-5331725
Email: ihadar@painreform.com

Attachments

  • Original Link
  • Permalink

Disclaimer

PainReform Ltd. published this content on 12 April 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 April 2024 07:31:07 UTC.